Introduction {#S0001}
============

Influenza, an acute respiratory disease caused by the influenza virus, remains a major global health concern. An estimated 5--10% of adults and 20--30% of children are affected worldwide, with 250,000--500,000 deaths annually.[@CIT0001] Therefore, antiviral therapy is very important for lowering the prevalence and mortality of influenza epidemics; among these therapies, oral oseltamivir and intravenous peramivir are currently mainly used.[@CIT0002]

Peramivir was the first intravenous neuraminidase inhibitor (NAI) approved by the US Food and Drug Administration (FDA) for the treatment of influenza.[@CIT0003] Data from randomized controlled trials have shown that peramivir is safe and well-tolerated in uncomplicated influenza, with similar or superior clinical efﬁcacy to those of placebo and oseltamivir.[@CIT0004]--[@CIT0006] Oseltamivir and zanamivir are not easy to administrate to severely ill patients compared to peramivir, which is injected intravenously. Peramivir has shown effectiveness in severely ill patients with influenza.[@CIT0007]--[@CIT0009] Some studies reported similar efficacies between peramivir and oseltamivir in severe influenza or influenza in high-risk patients.[@CIT0010],[@CIT0011] In particular, hospitalized patients may be more likely to have severe clinical features with complications such as pneumonia. These patients may also have clinical benefits such as reduced mortality and shorter duration of hospital stay with anti-influenza medications.[@CIT0012]--[@CIT0015] However, there is still a lack of studies comparing the efficacy of peramivir and oseltamivir in hospitalized patients with relatively severe influenza infections.

Therefore, this study aimed to compare the clinical efﬁcacy of peramivir with that of oseltamivir in hospitalized patients with inﬂuenza.

Patients and Methods {#S0002}
====================

Patients {#S0002-S2001}
--------

This retrospective cohort study examined data from patients with seasonal influenza hospitalized in five teaching hospitals and one secondary hospital between August 2017 and May 2018. All eligible patients were at least 18 years of age who had laboratory (e.g., reverse-transcriptase-polymerase chain reaction \[RT-PCR\] or influenza rapid antigen test) confirmed influenza A or B virus infections.

Treatment including antiviral choice was decided by the primary physicians. The patients were stratified into standard dose (300 mg, single-dose) peramivir, high-dose (exceeding 300 mg, single or multiple doses) peramivir, and oseltamivir (75 mg, twice daily for 5 days) groups. When the single dose was reduced to less than 300mg according to renal function, it was regarded as standard dose.

The use of oral or parenteral antibiotics and antipyretics was permitted at the discretion of the patient's primary physician.

Each variable was compared between the three groups and patients treated with both drugs were excluded.

This study was approved by institutional review boards of Gachon University Gil Medical Center (GBIRB2018-132), in accordance with the Declaration of Helsinki, and by the institutional review boards of other hospitals. The Committee waived the signatures of informed consents by the patients whose records were reviewed, as this was a noninterventional, observational study with data management processed anonymously.

Definitions {#S0002-S2002}
-----------

Influenza-like illness (ILI) was defined as the sudden onset of fever (38°C) and respiratory symptoms, as well as headache, arthralgia, or myalgia. Influenza infection was defined as patients with ILI symptoms whose nasal swab, throat swab, nasal aspirate, or sputum specimens were positive in either rapid diagnostic test kits licensed in Korea (SD Influenza Antigen kit \[Standard Diagnostics, Inc., Yongin, Korea\]) or RT-PCR tests. Co-morbidities were defined as the presence of one or more pre-existing major medical conditions such as malignancy, chronic lung disease, steroid or immunosuppressant use, asthma, chronic heart disease, diabetes mellitus, etc and measured according to the Charlson ﻿comorbidity ﻿index (CCI)[@CIT0016] using clinical data. Pneumonia was defined as the presence of both clinical symptoms and radiographically-identified pulmonary infiltrations. Acute Physiologic and Chronic Health Evaluation (APACHE) II score, the Sequential Organ Failure Assessment (SOFA) score, partial pressure of arterial oxygen (PaO2), partial pressure of arterial carbon dioxide (PaCO2), and arterial oxygen saturation (SaO~2)~ was assessed to evaluate severity of illness on the day of admission.

Time from first symptom onset to first dose of peramivir/oseltamivir and durations of oseltamivir/peramivir administration were also recorded.

Defervescence was defined as the lack of a fever (≤37.5°C) for more than 24 h and the date of defervescence was defined as the first day of defervescence.

The primary outcome was defervescence within three days from the first administration of peramivir or oseltamivir. The secondary outcomes were mortality and duration of hospitalization/intensive care unit (ICU) stay.

Statistical Analysis {#S0002-S2003}
--------------------

The means and standard deviation (SD) were calculated for continuous variables, including age, weight, duration of hospital stay, and duration of fever. Percentages were calculated for categorical variables including sex, influenza type, comorbidities, existence of symptoms, development of organ failure, and treatment modalities. Analysis of variation (ANOVA) and Fisher's exact tests were used to compare continuous and categorical variables, respectively, between the three groups. Kruskal--Wallis tests were used as an alternative to ANOVA when the data were not normally distributed.

Multivariate logistic regression was used to identify the risk factors for 30-day mortality. The multivariable models were developed using the backward stepwise method. After univariate analysis, variables with *p* \< 0.05 were considered significant; variables with *p* \< 0.1 were considered borderline significant and both were retained in the final multivariate prediction model. All significance testing was two tailed, and *p* \< 0.05 was considered statistically significant. All analyses were performed using IBM SPSS Statistics for Windows, version 24.0 (IBM Corp., Armonk, NY, USA).

Results {#S0003}
=======

Baseline and Clinical Characteristics {#S0003-S2001}
-------------------------------------

Of 542 enrolled patients, 251 received the standard dose (300 mg, single-dose) of peramivir, 42 received peramivir doses exceeding 300 mg (high-dose), and 249 were administered oseltamivir. The distribution of the patients according to the peramivir dose administered in the high-dose group was 13 cases (31.0%) administered multiple 300-mg doses, 12 cases (28.6%) administered a single 600-mg dose, and 17 cases (40.5%) administered multiple 600-mg doses.

The patient demographic and clinical characteristics are shown in [Table 1](#T0001){ref-type="table"}. The peramivir group, both standard dose and high-dose groups, tended to include older patients compared to the oseltamivir group (70.52±15.03 vs. 71.19±15.29 vs. 66.20±16.72, *p*=0.005). There were more ICU admissions (43 (17.13%) vs. 13 (30.95%) vs. 21 (8.4%), *p*=0.000) and pneumonia cases (89 \[35.46%\] vs. 27 \[64.29%\] vs. 36 \[14.46%\], *p*=0.000) in the peramivir group, especially in the high-dose group, while chronic heart disease (24 \[9.56%\] vs. 4 \[9.52%\] vs. 46 \[18.47%\], *p*=0.010), chronic lung disease (27 \[10.76%\] vs. 1 \[2.38%\] vs. 59 \[23.69%\], *p*\<0.001), and chronic liver disease (12 \[4.78%\] vs. 4 \[9.52%\] vs. 29 \[11.65%\], *p*=0.020) were more prevalent in the oseltamivir group. However, Charlson's ﻿comorbidity ﻿index (CCI) did not differ significantly the three groups ([Table 1](#T0001){ref-type="table"}). The duration of illness before diagnosis differed between the three groups, with the peramivir groups, especially the high-dose group, having a longer duration (days) of illness than that of the oseltamivir group (2.54±2.94 vs. 3.17±2.49 vs. 2.11±1.50, *p*=0.011).Table 1Baseline Characteristics of All PatientsNumbers (%)Peramivir Group Standard Dose^a^ (n=251)Peramivir Group High Dose^b^ (n=42)Oseltamivir Group (n=249)*p*Sex, male127 (50.6)19 (45.24)115 (46.18)0.568Age, years (mean±SD)70.52±15.0371.19±15.2966.20±16.720.005Influenza Type0.016A143 (56.97)21 (50)166 (66.7)B104 (41.43)20 (47.62)83 (33.3)A and B4 (1.59)1 (2.38)0Co-morbiditiesChronic heart disease24 (9.56)4 (9.52)46 (18.47)0.010Chronic lung disease27 (10.76)1 (2.38)59 (23.69)\<0.001Chronic liver disease12 (4.78)4 (9.52)29 (11.65)0.020Chronic kidney disease36 (14.34)2 (4.76)26 (10.44)0.135Solid tumor41 (16.33)4 (9.52)37 (14.86)0.515Hematologic malignancy1 (0.40)1 (2.38)9 (3.61)0.038Diabetes73 (29.08)10 (23.81)67 (26.91)0.727CCI (mean±SD)2.00±2.281.48±1.762.10±1.980.212ICU admission at baseline43 (17.13)13 (30.95)21 (8.4)0.000Pneumonia at baseline89 (35.46)27 (64.29)36 (14.46)0.000Time from onset to treatment initiation^c^ (days, (mean±SD))2.54±2.943.17±2.492.11±1.500.011[^1]

The other clinical parameters are shown in [Table 2](#T0002){ref-type="table"}. The baseline laboratory parameters from available patients did not differ significantly between the three groups except for Sequential Organ Failure Assessment (SOFA) score (5.11±3.44 vs. 8.00±3.12 vs. 4.57±3.04, *p*=0.032) and creatinine clearance (67.81±34.41 vs. 69.50±36.86 vs. 83.21±46.94, *p*=0.0003). Acute Physiology, Age and Chronic Health Evaluation (APACHE) II scores were available in a few cases and tended to be higher in the peramivir group but this difference was not statistically significant (18.89±8.55 vs. 21.20±0.96 vs. 15.25±5.92, *p*=0.101).Table 2Laboratory Parameters from Available PatientsMean±SD, nPeramivir Group Standard Dose^a^ (n=251)Peramivir Group High Dose^b^ (n=42)Oseltamivir Group (n=249)*p*PaO2 (mmHg)76.49±33.12, (128)77.48±35.31, (21)78.20±31.95, (102)0.926PaCO2 (mmHg)37.34±9.61, (128)34.76±7.03, (21)35.50±10.07, (102)0.259SaO~2~ (%)92.39±6.54 (135)91.41±8.49 (22)93.22±5.64 (102)0.396SOFA score5.11±3.44 (61)8.00±3.12 (8)4.57±3.04 (35)0.032APACHE II score18.89±8.55 (18)21.20±0.96 (5)15.25±5.92 (32)0.101Creatinine clearance (mL/min)67.81±34.41(210)69.50±36.86(41)83.21±46.94 (245)0.0003[^2]

Clinical Outcomes {#S0003-S2002}
-----------------

There were no significant differences in defervescence rates within three days between the single-dose and high-dose peramivir and oseltamivir groups (167 \[66.53%\] vs. 24 \[57.14%\] vs. 178 \[71.49%\], *p*=0.141). The durations (days) of hospital (10.65±13.84 vs. 14.12±13.75 vs. 13.28±18.12, *p*=0.129) and ICU (9.60±13.17 vs. 10.62±10.63 vs. 11.26±11.53, *p*=0.868) stays were also not significantly different ([Table 3](#T0003){ref-type="table"}). No serious adverse effect was reported in any of the three groups.Table 3Clinical Outcomes from All PatientsNumbers (%)Peramivir Group Standard Dose^a^ (n=251)Peramivir Group High Dose^b^ (n=42)Oseltamivir Group (n=249)*p*Defervescence within 3 days167 (66.53)24 (57.14)178 (71.49)0.14130-Day mortality22 (8.76)5 (11.90)15 (6.02)0.299Duration of hospital stay (mean±SD)10.65±13.8414.12±13.7513.28±18.120.129Duration of ICU stay (mean±SD)9.60±13.1710.62±10.6311.26±11.530.868[^3]

The overall mortality was 7.74% (42/542) and there was no significant difference between three groups ([Table 3](#T0003){ref-type="table"}). The factors associated with defervescence rates within three days or 30-day mortality were evaluated in all patients. Time from first symptom onset to first dose of peramivir/oseltamivir was not associated with defervescence rates (*P* =0.33). Multivariate analysis revealed that only pneumonia (OR 2.32, 95% CI (1.49--3.61), *P*=0.000) was associated with defervescence rates within three days. ICU admission (odds ratio \[OR\] 5.81, 95% CI (2.70--12.50), *P*=0.000), high CCI (OR 1.32, 95% CI (1.12--1.55), *P*=0.001), and pneumonia (OR 10.94, 95% CI (4.45--26.89), *P*=0.000) were associated with 30-day mortality. ([Table 4](#T0004){ref-type="table"}).Table 4Multivariate Analysis of Factors Associated with 30-Day MortalityNumbers (%)Survivors (n=500)Non-Survivors (n=42)Multivariate OR (95% CI)*p*Age (mean±SD)67.90±16.0176.69±13.090.094ICU admission47(9.4)21(50%)5.81 (2.70--12.50)0.000Peramivir266(53.2)27(64.3)0.377CCI (mean±SD)1.91±2.053.00±2.511.32 (1.12--1.55)0.001Pneumonia118 (23.6)34 (81)10.94 (4.45--26.89)0.000[^4]

Discussion {#S0004}
==========

This study evaluated the clinical outcomes of hospitalized influenza patients administered peramivir or oseltamivir. Influenza infection can cause serious problems[@CIT0017] and ICU admission.[@CIT0017],[@CIT0018] Peramivir has been used since the 2009 pandemic to treat critically ill influenza patients.[@CIT0019] Since hospitalized patients, especially critically ill patients, may have difficulty in achieving appropriate drug levels with oral oseltamivir,[@CIT0020],[@CIT0021] intravenous peramivir can be an attractive option for clinicians. However, the few studies comparing the effectiveness of peramivir and oseltamivir in hospitalized influenza patients have reported similar efficacy[@CIT0011],[@CIT0022]. In a study conducted in an ICU, peramivir showed similar clinical efficacy to that of oseltamivir; however, the peramivir group had significantly more patients with shock and high SOFA score.[@CIT0011] A recent large prospective observational study showed that influenza related symptoms disappeared about 3 days after peramivir administration[@CIT0023] and it reflected quality of life in patients with influenza infection. In this study, we defined defervescence within 3 days as primary outcome because we thought that it is a good indicator of recovery of patient's quality of life.

The present study observed no significant differences in mortality or hospital or ICU stay durations between peramivir and oseltamivir. However, ICU admission and pneumonia, which are risk factors for mortality, were more prevalent in the peramivir group, especially in the high-dose group. The Korea Ministry of Food and Drug Safety (KMFDS) recommended the administration of a single 300-mg dose of peramivir to adult influenza patients with normal renal function during the study period.[@CIT0023]

Several studies showed that 300mg IV peramivir was noninferior to 600mg IV peramivir or oseltamivir or both.[@CIT0005],[@CIT0024],[@CIT0025] Thus, in the current study, most patients treated with peramivir received a single 300-mg dose, although physicians tended to administer higher doses to more severe patients. Moreover, age, another worse prognostic factor,[@CIT0011] was also higher in the peramivir group. These findings suggest the usefulness of peramivir in patients with severe influenza. Further studies are needed to determine the appropriate dose and duration in hospitalized patients with severe illness. The treatment cost of peramivir (300mg/single dose) and oseltamivir (75mg/10 capsules) were about 30--50 dollars and 13--25 dollars in Korea.

The time elapsed before the administration of antiviral medications was relatively long in this study, particularly in the high-dose peramivir group. As anti-influenza drugs are most effective when they are used within 48 hours,[@CIT0005],[@CIT0010] this delay could have affected the clinical outcomes. Despite this, all treatment groups showed similar clinical responses, indicating that high-dose peramivir may have a clinical benefit in these patients. Some studies have suggested that hospitalized patients may have advantages from antiviral therapy starting \>48 hours after symptom onset, although earlier initiation seems to be more effective.[@CIT0012]--[@CIT0014]

This study had some limitations. First, the study was a retrospective design. Therefore, severity and comorbidity were not evenly distributed between the two groups and the choice of oseltamivir or peramivir was decided by attending physicians. Moreover, laboratory parameters including severity scores such as SOFA and APACHE II could not be obtained from all patients. Although precise comparisons of clinical effectiveness between the three groups were not possible, peramivir showed similar efficacy in hospi talized patients despite the high prevalence of pneumonia and ICU admission.

Second, this study did not collect data on subjective symptoms. Because we collected only objective data considering the retrospective design, no data were available on important clinical indicators such as fever and cough, which may not accurately reflect the clinical situation. However, considering the hospitalization, we did have data on regularly checked body temperatures, which are an objective indicator to reflect improvement in influenza; thus, this method was used to accurately confirm the clinical improvement.

Conclusion {#S0005}
==========

Treatment of influenza with either peramivir or oseltamivir in hospitalized adults resulted in generally similar clinical outcomes. Treatment with peramivir showed good clinical response in influenza patients with pneumonia or admitted to the ICU.
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[^1]: **Notes**: ^a^300 mg, single dose; ^b^exceeding 300 mg, single or multiple doses; ^c^time from first symptom onset to first dose of peramivir/oseltamivir.

    **Abbreviations:** CCI, Charlson ﻿comorbidity ﻿index; SD, standard ﻿deviation; ICU, ﻿intensive ﻿care ﻿unit.

[^2]: **Notes:** ^a^300 mg, single dose; ^b^exceeding 300 mg, single or multiple doses.

    **Abbreviations:** PaO~2~, partial pressure of arterial oxygen; PaCO~2~, partial pressure of arterial carbon dioxide; SaO~2~, arterial oxygen saturation; SOFA, ﻿sequential ﻿organ ﻿failure ﻿assessment; APACHE, ﻿acute ﻿physiologic and ﻿chronic ﻿health ﻿evaluation.

[^3]: **Notes:** ^a^300mg, single dose; ^b^exceeding 300mg, single or multiple doses.

    **Abbreviations:** SD, standard deviation; ICU, ﻿intensive care ﻿unit.

[^4]: **Abbreviations:** CCI, Charlson comorbidity ﻿index; SD, ﻿standard ﻿deviation; ICU, ﻿intensive ﻿care ﻿unit.
